Overall verdict
Buy
6.5/10
1-year performance
-31.91%
Score breakdown
Down 31.9% over 1 year, 15% of the 52-week range.
Strongest: Shareholder return 9.6/10. Weakest: Growth 3.1/10.
25 analysts, target +0.2% vs the price.
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas.
The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management.
The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Sector
Health Care
Industry
Pharmaceuticals
Primary listing
Omxcop
Denmark
CEO
Mr. Maziar Mike Doustdar B.A.
Founded
1923
Employees
68 794
Revenue / employee
4.6M DKK
Next earnings
November 4, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
409.95 DKK
52-week low
224.25 DKK
1-year performance
-31.91%
Declining
Year-to-date performance
-23.10%
Declining
Drawdown
-38.29%
Major drawdown
Position in the 52-week range
15% of range
Range: 610.38 DKK - 618.10 DKK (comparables only)
The price implies growth of 1.21% per year; the company grows at 20.66%.
Gross margin 80.6%, net margin 35.3%, ROIC 38.9%, ROE 59.8%.
Net margin
35.35%
Exceptional
Sector 9.43%|S&P 12.97%
Gross margin
80.65%
Exceptional
Return on equity (ROE)
59.82%
Exceptional
Sector 6.16%|S&P 16.52%
Return on invested capital (ROIC)
38.92%
Exceptional
Free cash flow margin (FCF)
22.63%
Exceptional
Profit-to-cash conversion (FCF conversion)
0.64x
Fair
Margin stability
1.3 pts
Very steady
Revenue to net income
Growth
3.1/10Revenue up 2.1% over 1 year, 19.5% a year over 5, EPS 20.7% a year over 5.
Revenue (trailing 12 months)
329Md DKK
Revenue growth (1y)
2.12%
Moderate
Revenue growth (3y)
74.66%
Strong
EPS growth (1y)
-20.61%
Declining
EPS CAGR (5y)
20.66%
Exceptional
EPS revisions (3 months)
3.10%
Revised up
Valuation
8.7/10P/E 9.7x, forward P/E 11.3x, EV/EBITDA 7.1x, PEG 0.47. The multiple sits in the 5th percentile of its own 5-year history.
P/E (TTM)
9.7x
Cheap
Sector 27.4x|S&P 23.3x
Forward P/E
11.3x
Fair
EV / EBITDA
7.1x
Cheap
Sector 16.1x|S&P 14.6x
PEG
0.47
Growth unpriced
Sector 1.05|S&P 0.86
Fair value (reverse DCF)
614.24 DKK
Deeply undervalued
P/E vs its own 5-year history
among the 5% lowest valuations
Far cheaper than usual
Market cap
1.1T DKK
Financial strength
8.7/10Cash covers 32.1% of the debt, net debt/EBITDA 0.7x.
Net debt / EBITDA
0.7x
Solid
Gearing (net debt / equity)
43.00%
Solid
Cash
43.7Md DKK
Cash / market cap
3.91%
Tight
Cash / total debt
32.10%
Solid
Interest coverage
30.3x
Very solid
Net debt
92.4Md DKK
Equity
215Md DKK
Closed daily candles, 2 years
Last close on September 25, 2026: 253.00 DKK
- MM20279.89
- MM50296.89
- MM200296.58
- RSI 1427.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.95%
200-day average slope, 3 months
-3.82%
50-day average slope, 1 month
-5.23%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.18 % per day
Volatility change
+2.19%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 22.34 (19) | 21.66 (20) | 300 167 (27) | 144 506 (22) | 98 835 (19) |
| 2027 | 21.60 (19) | 21.86 (20) | 304 116 (27) | 144 396 (22) | 95 474 (19) |
Amounts in millions of DKK, EPS in DKK per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 509 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BMY | 7.4 | 7.8 | 125Md USD | 13.5x | 18.9 % | 5.8 % | 14.3 % | 1.9x | 9.2 % | 42.3 % | ||
| 2 | LLY | 6.7 | 6.0 | 1.1T USD | 39.1x | 33.5 % | 47.7 % | 39.8 % | 1.2x | 1.7 % | 60.4 % | ||
| 3 | NOVN | 6.5 | 6.4 | 263Md USD | 22.8x | 23.3 % | -2.0 % | 17.2 % | 1.0x | 6.2 % | 22.6 % | ||
| 4 | NOVO B | 6.5 | 7.6 | 170Md USD | 9.7x | 35.3 % | 2.1 % | 38.9 % | 0.7x | 6.7 % | -31.9 % | ||
| 5 | JNJ | 6.2 | 5.7 | 649Md USD | 31.2x | 21.5 % | 6.6 % | 17.5 % | 0.9x | 3.4 % | 53.1 % | ||
| 6 | ROP | 6.2 | 5.7 | 351Md USD | 23.5x | 20.3 % | 1.7 % | 21.8 % | 0.8x | 5.2 % | 38.2 % | ||
| 7 | AZN | 5.5 | 6.5 | 254Md USD | 25.2x | 17.0 % | 5.8 % | 14.3 % | 1.2x | 4.3 % | 12.4 % | ||
| 8 | MRK | 5.4 | 4.4 | 365Md USD | 118.4x | 4.8 % | 4.9 % | 3.6 % | 1.2x | 4.4 % | 86.5 % | ||
| 9 | PFE | 4.9 | 4.6 | 161Md USD | 37.3x | 6.8 % | 2.6 % | 3.0 % | 2.3x | 6.8 % | 19.0 % |
